Report ID: 10078325 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Cancer Biomarkers Industry was valued at USD 13.50 Billion in the year 2017. Global Cancer Biomarkers Industry is further estimated to grow at a CAGR of 14% from 2019 to reach USD 37.94 Billion by the year 2025.
The Global Cancer Biomarkers is segmented as by cancer type, by profiling technology, by biomarkers, and by region. On the basis of the type of cancer the Industry is segmented as Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer and Others of which breast cancer holds the highest Industry share.
On the basis of Profiling Technology, the Global Cancer Biomarkers Industry is segmented as OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, and Bioinformatics of which OMICS Technology is expected to hold the highest Industry share in the forecasted period.
On the other hand, by a Biomarkers Type, the Industry is segmented as Protein Biomarkers, Genetic Biomarkers and others for this protein biomarker segment are expected to grow at highest CAGR during the year 2019-2025. The large share of this segment is mainly attributed to the tremendous potential of protein biomarkers in cancer detection.
Major market players in Cancer Biomarkers Industry are 23andMe, Agilent Technologies, Abbott Laboratories Inc., Biomerieux, Hologic Inc., Roche Holding AG, Illumina Inc., Roche Diagnostics, GE Healthcare, Bio-Rad Laboratories, and brief information of 10 companies will be provided in the report.
SWOT Analysis of Cancer Biomarkers Industry:
Strength:
Increased Incidences of Cancer Globally
Higher Acceptance for Treatment in Developing Regions
Weakness:
High Cost of Diagnosis and Reimbursement Issues
Opportunities:
Technological and Scientific advancements
Emerging Economies
Threats:
Unfavorable Regulatory framework and policies
Cancer Biomarkers Industry Segmentation:
By Cancer Type
• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Cervical Cancer
• Others
By Profiling Technology
• OMICS Technology
• Imaging Technology
• Immunoassays
• Cytogenetics
• Bioinformatics
By Biomarkers Type
• Protein Biomarkers
• Genetic Biomarkers
• Others
By Region
• North America
o USA
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Rest of Europe
• APAC
o China
o India
o Japan
o Rest of Asia-Pacific
• RoW
o Latin America
o Middle East & Africa
ㄮ
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10078325 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
